Top Markets
Coin of the day
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Classificação em ações #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Preço da ação
$0.15
Valor de mercado
$4.96M
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
CA
Negociar Intellipharmaceutics International Inc. (IPCIF)

Categoria

Histórico de desdobramentos de ações de Intellipharmaceutics International Inc. (IPCIF)
As ações Intellipharmaceutics International Inc. (símbolo: IPCIF) passaram por um total de 3 desdobramentos.
O desdobramento mais recente ocorreu em Sep 14, 2018.
Uma ação IPCIF comprada antes de Apr 17, 2007 equivaleria hoje a 0.00066 ações IPCIF.
Lista de desdobramentos de ações
Ano Desdobramento Multiplicador Multiplicador cumulativo
2018-09-14 1:10 x0.1 x0.00066
2009-10-22 33:500 x0.066 x0.0066
2007-04-17 1:10 x0.1 x0.1
Desdobramentos de ações de empresas semelhantes ou concorrentes
Empresa Número de desdobramentos de ações Multiplicador cumulativo País
5 x199
DK
1 x2
US
0 -
US
0 -
BE
0 -
NL